---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-22-000084"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:10:21.932424+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio Q2 net loss $56.5M; seralutinib Phase 2 readout on track for Nov/Dec 2022

## Summary
- Net loss of $56.5M ($0.74/share) vs $59.8M ($0.80/share) in Q2 2021.
- Cash, equivalents & marketable securities $222.2M as of June 30; pro forma $342M after $120M July 2022 private placement.
- Seralutinib Phase 2 TORREY topline data expected second half November or first half December 2022.
- GB5121 Phase 1b/2 STAR CNS study in PCNSL dosed first patient.
- Commencing investment in registrational Phase 3 program for seralutinib targeted for Q3 2023.

## SEC filing metadata
- accession: 0001728117-22-000084
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811722000084/0001728117-22-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811722000084/goss-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-22-000084
- JSON: https://secwatch.observer/filing/0001728117-22-000084.json
- Plain text: https://secwatch.observer/filing/0001728117-22-000084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.